National Institute of Biological Sciences has disclosed pyrazole urea derivatives acting as inhibitor of nuclear factor κB kinase subunit ε (IKBKE; IKK-i) and/or TANK-binding kinase 1 (TBK1; NAK; T2K) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity and inflammatory disorders.
The estrogen receptor-positive (ER+) subtype accounts for 70% of all mammary carcinoma (MC) cases. ER+ MC patients display a prolonged clinical dormancy state, with a 70% recurrence 5-20 years after clinical remission and high mortality.
Previous studies revealed a positive correlation between O-GlcNAcylation and tumor growth via the stabilization of target proteins, with O-GlcNAcylation transferase (OGT) being the only enzyme capable of catalyzing the addition of O-GlcNAcylation to these proteins. Scientists at Sun Yat-Sen University and affiliated organizations investigated the role of OGT in the progression and drug resistance of multiple myeloma.
Neuroblastoma, an aggressive malignancy originating from neural crest cells, accounts for 15% of cancer-related deaths in children. Treatment strategies include systemic chemotherapy, radiation or immunotherapy with anti-GD2 antibodies, all with severe side effects and long-term toxicity. Retinoic acid (RA) has been shown to promote neuroblastoma growth inhibition while suppressing MYCN oncogene expression. However, its effect is reversible, and tumor regrowth may occur.
Onkure Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities, scoliosis and PIK3CA related overgrowth spectrum (PROS), among others.
Selenoprotein O (SELENOO) is an antioxidant mitochondrial enzyme that transfers AMP from ATP to protein substrates in a post-translational process known as AMPylation.
Sotio Biotech AS is exercising an option under a license and option agreement to obtain a license to Synaffix BV’s technology to develop two bispecific antibody-drug conjugate (ADC) programs for solid tumors.
Sutro Biopharma Inc. has announced plans to prioritize its three wholly owned preclinical programs in its next-generation antibody-drug conjugate (ADC) pipeline, while deprioritizing additional investment into development of luveltamab tazevibulin across all indications.
Researchers from Soochow University and affiliated organizations presented data from a study that aimed to investigate the role of cyclic GMP-AMP synthase (cGAS) in tumorigenesis and tumor progression.
Qingdao Putaike Biomedical Technology Co. Ltd. has described androgen receptor full length (AR-FL) and/or androgen receptor variant 7 (AR-v7) degradation inducers reported to be useful for the treatment of acne vulgaris, androgenic alopecia, cancer, hirsutism, metabolic diseases, polycystic ovary syndrome, precocious puberty and benign prostatic hyperplasia, among others.
RSS
